Sane R - Search Results

1

Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.

Uguen M, Hilton M, Farid-Kapadia M, Datye A, Chohan S, Carlucci C, Dixon M, Elze M, Chen Y, Cheung KWK, Sane R, Zheng M, Choi Y. Uguen M, et al. Among authors: sane r. J Biopharm Stat. 2023 Nov 2;33(6):800-811. doi: 10.1080/10543406.2022.2162071. Epub 2023 Jan 13. J Biopharm Stat. 2023. PMID: 36637189 Clinical Trial.

2

The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.

Takahashi RH, Malhi V, Liederer BM, Cho S, Deng Y, Dean B, Nugteren J, Yost E, Al-Sayah MA, Sane R, Kshirsagar S, Ma S, Musib L. Takahashi RH, et al. Among authors: sane r. Drug Metab Dispos. 2023 Oct;51(10):1332-1341. doi: 10.1124/dmd.122.001175. Epub 2023 Jul 31. Drug Metab Dispos. 2023. PMID: 37524543

3

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics.

Cheung KWK, Tang Y, Anders D, Barata T, Scalori A, Agarwal P, Sane R, Cheeti S. Cheung KWK, et al. Among authors: sane r. Pharmaceutics. 2024 Apr 20;16(4):564. doi: 10.3390/pharmaceutics16040564. Pharmaceutics. 2024. PMID: 38675225 Free PMC article.

4

Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors.

Velasquez E, Kassir N, Cheeti S, Kuruvilla D, Sane R, Dang S, Miles D, Lu J. Velasquez E, et al. Among authors: sane r. Front Artif Intell. 2024 Jun 11;7:1412865. doi: 10.3389/frai.2024.1412865. eCollection 2024. Front Artif Intell. 2024. PMID: 38919267 Free PMC article.

5

Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer.

Sutaria DS, Rasuo G, Harris A, Johnson R, Miles D, Gallo JD, Sane R. Sutaria DS, et al. Among authors: sane r. Pharmaceutics. 2022 Oct 1;14(10):2101. doi: 10.3390/pharmaceutics14102101. Pharmaceutics. 2022. PMID: 36297536 Free PMC article.

6

Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.

Bowman C, Dolton M, Ma F, Cheeti S, Kuruvilla D, Sane R, Kassir N, Chen Y. Bowman C, et al. Among authors: sane r. CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):660-672. doi: 10.1002/psp4.13114. Epub 2024 Mar 13. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38481038 Free PMC article.

7

Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation.

Harun R, Sane R, Yoshida K, Sutaria DS, Jin JY, Lu J. Harun R, et al. Among authors: sane r. JCO Clin Cancer Inform. 2023 Apr;7:e2200168. doi: 10.1200/CCI.22.00168. JCO Clin Cancer Inform. 2023. PMID: 37116107 Free PMC article.

8

Evaluation of Patient-Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules.

Mandlekar S, Sutaria DS, Yang X, Johnson R, Zou Y, Dean B, Chen L, Sane R, Williams K, Cardenas A, Simon M, Fischer S. Mandlekar S, et al. Among authors: sane r. Clin Pharmacol Ther. 2024 Sep;116(3):782-794. doi: 10.1002/cpt.3272. Epub 2024 Apr 26. Clin Pharmacol Ther. 2024. PMID: 38671563

9

A Phase I Study of the Pharmacokinetics and Safety of Ipatasertib, an Akt Inhibitor in Chinese Patients With Locally Advanced or Metastatic Solid Tumors.

Zhang J, Liu R, Sutaria D, Sane R, Fan M, Wang R, Song G, Chen K, Arzumanova K, Hu X. Zhang J, et al. Among authors: sane r. Clin Ther. 2024 Dec 24:S0149-2918(24)00369-2. doi: 10.1016/j.clinthera.2024.11.021. Online ahead of print. Clin Ther. 2024. PMID: 39721851

10

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.

Matsubara N, de Bono J, Sweeney C, Chi KN, Olmos D, Sandhu S, Massard C, Garcia J, Chen G, Harris A, Schenkel F, Sane R, Hinton H, Bracarda S, Sternberg CN. Matsubara N, et al. Among authors: sane r. Clin Genitourin Cancer. 2023 Apr;21(2):230-237.e1. doi: 10.1016/j.clgc.2023.01.001. Epub 2023 Jan 7. Clin Genitourin Cancer. 2023. PMID: 36697317 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters